Meeting
2015 Gastrointestinal Cancers Symposium
Analysis of the GERCOR index in KRAS Exon2 WT patients with mCRC treated with salvage-line cetuximab-based chemotherapy: HGCSG0901.
Authors
Ayumu Hosokawa
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Toyama, Japan
Ayumu Hosokawa , Satoshi Yuki , Hiroshi Nakatsumi , Kazuteru Hatanaka , Yasushi Tsuji , Hiroyuki Okuda , Yasuo Takahashi , Jun Konno , Kazunori Eto , Yasuyuki Kawamoto , Norikazu Sonoda , Yasushi Sato , Mayuko Saito , Takuto Miyagishima , Shinichiro Ikeda , Koji Yoshizaki , Takahide Sasaki , Soh Saitoh , Yuh Sakata , Yoshito Komatsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 781)
DOI
10.1200/jco.2015.33.3_suppl.781
Abstract #
781
Poster Bd #
F19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase III FIRE-4 study (AIO KRK-0114): Evaluation of first-line treatment efficacy of FOLFIRI/cetuximab in patients with RAS-WT mCRC receiving the first cycle of treatment with chemotherapy only.
First Author: Sebastian Stintzing
Poster
2018 Gastrointestinal Cancers Symposium
Single nucleotide polymorphisms of mir-608, LCS-6, and overall survival in the MAGIC trial.
First Author: Elizabeth Catherine Smyth
Poster
2017 Gastrointestinal Cancers Symposium
Effect of subsequent chemotherapy on overall survival in first-line chemotherapy with targeted agents for patients with metastatic colorectal cancer: Systematic review and meta-analysis of randomized control trials.
First Author: Daisuke Sakai
Poster
2014 Gastrointestinal Cancers Symposium
Analysis of Kohne's prognostic index in KRAS wild-type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.
First Author: Ayako Doi